Table 2. Summary of the most common treatment-emergent adverse events occurring in ≥ 10% of all patients.

TEAE, n (%)	Dose-escalation cohort Dose, mg/m2				Dose-expansion cohort		Total (N = 38)
	260 (N = 6)	340 (N = 4)	440 (N = 3)	570 (N = 6)	All (N = 19)	GC (N = 14)
Nausea	1 (16.7)	2 (50)	0 (0)	3 (50)	8 (42.1)	4 (28.6)	14 (36.8)
Vomiting	1 (16.7)	1 (25.0)	0 (0)	1 (16.7)	10 (52.6)	6 (42.9)	13 (34.2)
Decreased appetite	1 (16.7)	1 (25.0)	1 (33.3)	0 (0)	8 (42.1)	5 (35.7)	11 (28.9)
Constipation	2 (33.3)	0 (0)	1 (33.3)	1 (16.7)	4 (21.1)	2 (14.3)	8 (21.1)
Fatigue/asthenia	3 (50)	0 (0)	1 (33.3)	0 (0)	4 (21.1)	2 (14.3)	8 (21.1)
Abdominal pains	1 (16.7)	0 (0)	1 (33.3)	0 (0)	6 (31.5)	2 (14.3)	8 (21.1)
Pyrexia	4 (66.7)	0 (0)	0 (0)	0 (0)	3 (15.8)	1 (7.1)	7 (18.4)
Injection site reaction/phlebitis	1 (16.7)	0 (0)	0 (0)	1 (16.7)	5 (26.3)	4 (28.6)	7 (18.4)
Back pain	3 (50.0)	0 (0)	0 (0)	0 (0)	2 (10.5)	2 (14.3)	5 (13.2)
Diarrhea	0 (0)	0 (0)	0 (0)	0 (0)	5 (26.3)	4 (28.6)	5 (13.2)
Cancer pain	0 (0)	0 (0)	1 (33.3)	2 (33.3)	1 (5.3)	1 (7.1)	4 (10.5)
Edema, peripheral	0 (0)	0 (0)	0 (0)	1 (16.7)	3 (15.8)	2 (14.3)	4 (10.5)
Insomnia	1 (16.7)	0 (0)	0 (0)	0 (0)	3 (15.8)	2 (14.3)	4 (10.5)
Rash	2 (33.3)	1 (25.0)	0 (0)	0 (0)	1 (5.3)	1 (7.1)	4 (10.5)
Cough	2 (33.3)	1 (25.0)	0 (0)	0 (0)	1 (5.3)	1 (7.1)	4 (10.5)

GC, gastric cancer; TEAE, treatment-emergent adverse events.